{"id":"W2936127489","doi":"10.1016/s2352-3018(19)30053-0","title":"Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial","year":2019,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":105,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; National Institutes of Health; Gilead Sciences; Merck; National Institute of Allergy and Infectious Diseases; Delaney AIDS Research Enterprise; Henry M. Jackson Foundation","keywords":"Medicine; Placebo; Human immunodeficiency virus (HIV); Antibody; Double blind; Internal medicine; Immunology; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005632579,0.0002441072,0.001111335,0.0001252478,0.0001133885,0.00002211752,0.000223417,0.0001303896,0.000152666],"category_scores_gemma":[0.00004462366,0.0001299135,0.0001107946,0.0001609147,0.0002519093,0.00008351021,0.00005299242,0.0003075951,0.0001984815],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002939461,"about_ca_system_score_gemma":0.00007380991,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001839392,"about_ca_topic_score_gemma":0.0001118232,"domain_scores_codex":[0.9982376,0.0004598421,0.0004114544,0.0003158628,0.00006941215,0.0005058565],"domain_scores_gemma":[0.9985715,0.0007710942,0.0001791629,0.0003943138,0.0000491988,0.00003472835],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9861422,0.0006325394,0.002700559,0.00003410899,0.0007937432,0.00002337299,0.001211907,0.00001550505,0.00700966,0.0001024551,0.0003766541,0.0009573081],"study_design_scores_gemma":[0.9892853,0.001328162,0.0008878486,0.0001680541,0.0001448219,0.00002937637,0.0001352587,0.00001903298,0.00716373,0.000005914873,0.0006863764,0.0001461226],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904073,0.001032082,0.000007972007,0.0010178,0.00008062633,0.005040383,0.0001460278,0.00003937597,0.002228422],"genre_scores_gemma":[0.9969318,0.0004898664,0.00002154551,0.00003264053,0.00005393058,0.0001372301,0.000296125,0.00001690675,0.002019938],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006524506,"threshold_uncertainty_score":0.5297719,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02335166505464427,"score_gpt":0.301349708916011,"score_spread":0.2779980438613668,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}